Posted in | News | Uranium

Vena Resources Reports Initial Results from Macusani Uranium Properties

Vena Resources has announced the preliminary results of the third major drilling at the Macusani properties of Minergia., jointly owned by Vena and Cameco.

Vena completes approximately 4,000 meters of drilling, that includes 16 holes at the Isivilla prospect and 11 holes at the Tantamaco prospect. Two track mounted machines are being used and received assays for the first 14 holes.

The drilling at Tantamaco extends higher grade zone intersecting 1.4 lbs/t U3O8 over 300 meters to the west and 150 meters to the south, around hole TA-2010-79. Several preliminary holes were at a distance of  50 meter x 50 meter gaps to confirm the reliability of the 40 meter thick scattered zone within B horizon of Yapamayo rhyolite pyroclastic. At present, Vena plans to continue extending the zone to south with a series of holes spaced at 100 meter x 100 meter intervals.

Vena encounters low uranium values from the initial assay results of seven Isivilla holes that were drilled near IS-06 hole. Drilling on the northern tier of holes identified increased uranium mineralization towards the west. An additional hole is drilled 200 meters to the west of IS-027 based on holes IS-026 and IS-027. When this hole is completed then the drill will move to Tantamaco for resource expansion program.

The higher grade zone at Tantamaco continues to south and west and with the addition of second drill, there should be rapid expansion of resource base. The Isivilla drilling indicates higher grade uranium zone and the next drilling will be planned to fill in between holes IS-06 and IS-27.


Joel Scanlon

Written by

Joel Scanlon

Joel relocated to Australia in 1995 from the United Kingdom and spent five years working in the mining industry as an exploration geotechnician. His role involved utilizing GIS mapping and CAD software. Upon transitioning to the North Coast of NSW, Australia, Joel embarked on a career as a graphic designer at a well-known consultancy firm. Subsequently, he established a successful web services business catering to companies across the eastern seaboard of Australia. It was during this time that he conceived and launched News-Medical.Net. Joel has been an integral part of AZoNetwork since its inception in 2000. Joel possesses a keen interest in exploring the boundaries of technology, comprehending its potential impact on society, and actively engaging with AI-driven solutions and advancements.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Vena Resources Inc.. (2019, February 18). Vena Resources Reports Initial Results from Macusani Uranium Properties. AZoMining. Retrieved on February 27, 2024 from

  • MLA

    Vena Resources Inc.. "Vena Resources Reports Initial Results from Macusani Uranium Properties". AZoMining. 27 February 2024. <>.

  • Chicago

    Vena Resources Inc.. "Vena Resources Reports Initial Results from Macusani Uranium Properties". AZoMining. (accessed February 27, 2024).

  • Harvard

    Vena Resources Inc.. 2019. Vena Resources Reports Initial Results from Macusani Uranium Properties. AZoMining, viewed 27 February 2024,

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Azthena logo powered by Azthena AI

Your AI Assistant finding answers from trusted AZoM content

Azthena logo with the word Azthena

Your AI Powered Scientific Assistant

Hi, I'm Azthena, you can trust me to find commercial scientific answers from

A few things you need to know before we start. Please read and accept to continue.

  • Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
  • Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
  • Large Language Models can make mistakes. Consider checking important information.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.